Sentry Investment Management LLC Sells 60 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sentry Investment Management LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 560 shares of the biopharmaceutical company’s stock after selling 60 shares during the period. Sentry Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $492,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of REGN. Markel Corp boosted its holdings in Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Markel Corp now owns 80,300 shares of the biopharmaceutical company’s stock valued at $56,083,000 after purchasing an additional 1,000 shares during the period. Cibc World Market Inc. boosted its holdings in Regeneron Pharmaceuticals by 1.4% in the 1st quarter. Cibc World Market Inc. now owns 6,416 shares of the biopharmaceutical company’s stock valued at $4,481,000 after purchasing an additional 86 shares during the period. Blair William & Co. IL boosted its holdings in Regeneron Pharmaceuticals by 18.4% in the 1st quarter. Blair William & Co. IL now owns 1,431 shares of the biopharmaceutical company’s stock valued at $999,000 after purchasing an additional 222 shares during the period. Sequoia Financial Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 23.1% in the 1st quarter. Sequoia Financial Advisors LLC now owns 495 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 93 shares during the period. Finally, Baird Financial Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 100.9% in the 1st quarter. Baird Financial Group Inc. now owns 36,529 shares of the biopharmaceutical company’s stock valued at $25,513,000 after purchasing an additional 18,345 shares during the period. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on REGN. Barclays increased their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. Cantor Fitzgerald restated a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. Bank of America increased their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday. Finally, BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $970.57.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total transaction of $95,422.00. Following the transaction, the director now directly owns 18,382 shares of the company’s stock, valued at $17,540,472.04. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 827 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the transaction, the director now directly owns 1,382 shares in the company, valued at $1,325,338. The disclosure for this sale can be found here. Insiders have sold 13,729 shares of company stock worth $13,124,641 over the last ninety days. Company insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.7 %

Shares of Regeneron Pharmaceuticals stock opened at $898.56 on Tuesday. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $98.63 billion, a P/E ratio of 25.86, a price-to-earnings-growth ratio of 2.64 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33. The company has a 50-day simple moving average of $956.81 and a 200 day simple moving average of $889.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same period in the prior year, the business earned $10.96 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.18 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.